Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune To Release Phase III Data By Year-End For Synagis Follow-On

This article was originally published in The Pink Sheet Daily

Executive Summary

MedImmune is on track to launch the newest member of its respiratory syncytial virus therapy franchise for the 2008–2009 respiratory virus season.

You may also be interested in...



MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23

While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.

MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23

While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.

Refrigerator-Stable FluMist Submitted For Young Children

MedImmune submitted a supplemental BLA seeking use of refrigerator-stable intranasal flu vaccine FluMist to inoculate children ages 12 months to 59 months, the company announced July 31

Related Content

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel